Over 125 patient organisations, including SMA UK, have signed an open letter calling on the UK Government to review and refresh, as a matter of urgency, the UK Strategy for Rare Diseases before the end of 2020.
Read full storyThank you to all who responded to this survey, and to Wickenstones for their analysis. The results and the results of our survey last year about the impact of SMA are now available and are being used to inform Biogen’s continuing work with NICE re: access to nusinersen. Read the results summary here.
Read full storyA huge thank you to all who personally gave copies of these and spoke about their lives to MPs at yesterday's Access to nusinersen parliamentary drop-in session. You can contact your MP, asking them to use these to write to NICE, Biogen and NHS England
Read full storyNusinersen has been routinely available to children with SMA Type 1 in Scotland since May 2018. This will continue. The SMC has now granted nusinersen ultra-orphan designation, allowing the treatment to be reviewed for those with SMA Types 2 and 3 through its new ultra-orphan appraisal process with the prospect of it being made available for at least three years while further outcome data is gathered.
Read full story
.jpg)
